This trial is completed!
Search for a recruiting clinical trial for your condition
You can access this
clinical trial
if you have
Renal Function or Liver Transplant
and you are
between 1 and 17
years old
Phase
3
This is a trial in the final phase before the treatment is released on the market.
Show me locations

The purpose

This study was designed to assess the evolution of renal function and to collect efficacy, safety, and tolerability data of everolimus in co-exposure with reduced CNI in paediatric liver transplant recipients.

Provided treatments

  • Drug: Introduction of everolimus with reduced cyclosporine or tacrolimus dose, the earliest 1 month and the latest 6 months after liver transplantation.
Tris trial is registered with FDA with number: NCT01598987. The sponsor of the trial is Novartis Pharmaceuticals and it is looking for 56 volunteers for the current phase.
Official trial title:
A 24-month, Multi-center, Single Arm, Prospective Study to Evaluate Renal Function, Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.